Agios Pharmaceuticals, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016. The unaudited results are for a clinical-stage biopharmaceutical company developing therapies for cancer and rare genetic metabolic disorders. Agios reported no product sales; substantially all revenue to date came from its Celgene collaborations. Financial figures below are in U.S. dollars, millions, unless stated otherwise.
Financial performance and liquidity
- Revenue: Collaboration revenue was $31.3 million, down 9% from $34.2 million. Q1 2016 included a $25.0 million AG-221 clinical-development milestone; the remaining $6.3 million was recognized under the applicable collaboration accounting. No product revenue was reported.
- Expenses and loss: R&D expense was $44.0 million, up 36%; G&A was $10.8 million, up 56%. Operating loss was $23.6 million versus $5.2 million, and net loss was $23.2 million versus $5.0 million. Basic and diluted net loss per share was $0.61 versus $0.13. Product margins are not applicable because the company had no product sales.
- Cash flow: Operating cash use was $19.0 million, compared with $25.6 million. Investing activities used $14.8 million, versus $45.0 million provided in Q1 2015; financing provided $1.1 million. Cash and cash equivalents decreased $32.7 million to $39.0 million.
- Liquidity and balance sheet: Cash, cash equivalents and marketable securities totaled $355.8 million at quarter-end, versus $375.9 million at December 31, 2015. Total assets were $396.1 million; stockholders’ equity was $332.4 million. The filing does not report borrowings or other debt. Current liabilities were $45.1 million, including $16.5 million of related-party deferred revenue.
- Other metrics: Stock-based compensation was $9.1 million, versus $5.1 million. The company reported no income-tax provision for either quarter.
Material changes versus Q1 2015
- Net loss widened by $18.2 million as operating expenses grew faster than collaboration revenue; R&D and G&A increased with development activity, staffing and facilities.
- Comparability is affected by unusual collaboration accounting in Q1 2015: Agios recognized $15.8 million on delivery of an ex-U.S. AG-120 license and an additional $5.1 million from a change in its estimate of AG-221 development-service effort. Including a $3.8 million reduction in R&D expense, the estimate change reduced that quarter’s net loss by $8.9 million.
- Q1 2016 revenue included the $25.0 million AG-221 milestone. Collaboration revenue excluding that milestone was $6.3 million as reported in the filing; cost reimbursements of $8.8 million were recorded as reductions of R&D expense, not revenue.
- Operating cash use was lower year over year, but cash and cash equivalents fell during Q1 2016 as the company made net purchases of marketable securities. Total cash and marketable securities also declined from year-end.
Outlook, commentary and risks
- Management expected existing cash, cash equivalents and marketable securities, anticipated interest income and Celgene expense reimbursements to fund operating and capital requirements until at least late 2017. This is an estimate dependent on development costs, collaboration reimbursements and other assumptions; the company said it would need substantial additional funding and had no committed external funding source other than its Celgene collaborations.
- Agios expected expenses and operating losses to increase as it advanced AG-221, AG-120, AG-881 and AG-348, developed AG-519 and expanded research and staffing. It stated that the timing and cost of completing development, regulatory approval and commercialization could not be reliably estimated.
- Planned development included a registration-enabling AG-120 phase 3 trial in frontline AML and a randomized phase 2 AG-120 trial in IDH1-mutant cholangiocarcinoma, both intended to start in the second half of 2016. The company expected initial AG-348 and AG-519 trial data in June 2016. These were forward-looking plans, not assured outcomes.
- Celgene concentration is material: substantially all historical revenue came from the collaboration. The 2010 Agreement’s discovery phase concluded in April 2016, ending further discovery-phase extension payments; the parties deferred selection of rights to certain discovery programs from April to June 2016. Collaboration termination, delays, or reduced reimbursements could affect development funding and liquidity.
- Key risks include clinical-trial efficacy, safety and enrollment; regulatory approval; manufacturing and third-party execution; intellectual-property protection and litigation; competition; future financing and dilution; and reimbursement and market acceptance. The filing reported no material change in internal control over financial reporting and effective disclosure controls at quarter-end.
- Clinical context: Agios and Celgene had initiated a phase 3 AG-221 trial; reported earlier AG-221 and AG-120 responses were from ongoing early-stage studies and are not proof of later-stage success. AG-348 was in a phase 2 patient trial, and AG-519 had entered a phase 1 healthy-volunteer trial.
Important facts for investors to verify
- Whether the deferred Celgene discovery-program rights selection was completed and what programs or economics resulted.
- Whether the $25.0 million AG-221 milestone was nonrecurring and how future collaboration revenue and reimbursements compare with development spending.
- Whether the late-2017 cash runway remains achievable as clinical programs advance, including the timing and amount of any additional financing.
- Progress, enrollment, safety and efficacy in the AG-221 and AG-120 trials, and the planned AG-120 phase 3 and cholangiocarcinoma trials.
- Whether the AG-348 and AG-519 programs meet enrollment, safety and development milestones, and whether trial data support further investment.